ZBB Energy Corporation (AMEX:ZBB) (the “Company”) announced recently that it received approval from the NYSE Amex (the “Exchange”) for listing of the shares in connection with the previously reported Stock Purchase Agreements with certain investors providing for the sale of a total of $2 million of the Company’s common stock, including $200,000 of these shares that are being purchased by members of the Company’s board of directors. The Company announced that the financing is scheduled to close January 12, 2011.
In other recent Company news, ZBB Energy Corporation announced an initial contract to design and deliver a hardened and transportable prototype version of ZBB’s ZESS POWR� PECC (Power & Energy Control Center). The prototype calls for a “ruggedized and transportable” version of the PECC, offering the ability to integrate multiple renewable energy sources for providing power in a variety of military applications that currently rely on power derived solely from diesel generators.
ZBB contracted with a leading provider of mobile defense solutions for this initiative to integrate the ZBB PECC technology as an integral component of a “self-contained” micro-grid that combines advanced energy storage, multiple renewable energy inputs and conventional diesel gen-sets into a resourceful and easily transportable power platform. The platforms are designed to be efficiently deployed to semi-permanent operating bases, remote facilities and other military locations able to leverage renewable energy sources to minimize the use of diesel generators. The rationale for developing a transportable, renewable energy-based power platform is predicated on the desire to significantly reduce the use of costly diesel fuel, which also poses logistical challenges and is often dangerous to transport through hostile regions.
ZBB Energy Corporation provides distributed intelligent power management platforms that directly integrate multiple renewable and conventional onsite generation sources with rechargeable zinc bromide flow batteries and other storage technology. This platform solves a wide range of electrical system challenges in global markets for various types of sites with utility, governmental, commercial, industrial and residential end customers. A developer and manufacturer of its modular, scalable and environmentally friendly power systems (”ZESS POWR�”), ZBB Energy was founded in 1998 and is headquartered in Wisconsin with offices also located in Perth, Western Australia.
Power3 Medical Products, Inc. (OTC.BB:PWRM) a leading proteomics company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases, today announced that company management believes it is making great progress in its focus on the development, sales, and marketing of its proprietary innovate diagnostic tests for breast cancer, pancreatic cancer, ovarian cancer, colon cancer, and certain neurodegenerative diseases, such as Alzheimer’s and Parkinson’s, to name a few.
Alzheimer’s is one, among the common sort of dementia, an over-all term regarding loss of memory and various other intellectual abilities serious enough to interfere with routine daily life. Alzheimer’s condition is the reason for 50 to seventy per cent of dementia cases.
Soon after skin cancer, breast cancer is easily the most widespread cancer recognized in females in the United States. But breast cancer rates have fallen recently, although medical professionals are not certain why. Even now, for women of all ages, breast cancer could be the condition they will fear most.
Parkinson’s disease (PD) is associated with a team of disorders called motor system disorders, which are the result of the losing of dopamine-producing brain cells. Some fundamental symptoms of PD are generally tremor, or moving in hands, arms, legs, jaw, and face; hardness, or maybe tightness of the limbs and trunk; bradykinesia, or slowness of movement; and postural lack of stability, or reduced balance as well as co-ordination. Since these symptoms become more evident, patients may have challenges walking, talking, or performing many other very simple tasks.
Power3 Medical Products, Inc. is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig’s disease). Power3 applies proprietary methodologies to discover and identify protein biomarkers associated with diseases. Through these processes, Power3 has developed a portfolio of products including BC-SeraPro�, a proteomic blood serum test for the early detection of breast cancer for which it has completed Phase I clinical trials, and NuroPro�, a proteomic blood serum test for the detection of neurodegenerative diseases, including Alzheimer’s, Parkinson’s, and ALS diseases, for which it is currently engaged in Phase II clinical trials.
No comments:
Post a Comment